Cargando…
Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
Autores principales: | Isenberg, David, Li, Yong, Wax, Stephen, Wofsy, David, Gordon, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179593/ http://dx.doi.org/10.1186/ar4669 |
Ejemplares similares
-
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015) -
Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016) -
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
por: Cogollo, Estafania, et al.
Publicado: (2015) -
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019) -
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)